SLNSilence Therapeutics Plc - ADR
$10.39
$0.11
(1.05%)
Closed $10.39
$0.1849
(1.78%)
After Hours
EarningsAug 6
Mkt Cap$490.77M
Vol696,727.00
Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential...
Yahoo! Finance: News
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.read more...
Benzinga
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6...
Business Wire
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026...
Business Wire
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor...
Business Wire
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the...
Business Wire
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in April
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 2,075,273...
MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock...
MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 1.8% - Here's What Happened
Silence Therapeutics (NASDAQ:SLN) Trading Down 1.8% - Here's Why...
MarketBeat
<
1
2
...
>